Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

US Must Rethink Biologic Naming Suffix, Says IGBA

27 Feb 2019

• By Dave Wallace

LightBulb — An Increasingly Isolated US Is Urged To Rethink Its Biologic Naming Approach • Source: Shutterstock

Related Content

Drop biologic suffixes IGBA urges US FDA

31 Aug 2018

Australia praised after rejecting biologic suffix

02 Feb 2018

Canadian Decision On Biological Names Leaves US As The Outlier

19 Feb 2019

Broad alliance queries FDA’s suffixes stance

06 Oct 2018

Additional Topics

United States International Biosimilars Regulation Biologics

More from Biosimilars

More from Products

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.